filoviru
serolog
diagnosi
epidemiolog
investig
hamper
due
unavail
valid
immunoassay
diagnost
perform
three
indirect
enzymelink
immunosorb
assay
ielisa
evalu
detect
igg
antibodi
ebola
viru
ebov
human
sera
one
ielisa
base
whole
ebov
antigen
wag
two
util
recombin
nucleocapsid
np
glycoprotein
gp
respect
valid
data
set
deriv
individu
sera
collect
south
africa
sa
repres
ebov
nonendem
countri
sera
collect
ebola
diseas
ebod
outbreak
sierra
leon
sl
categor
accord
compound
result
three
ielisa
real
time
reversetranscript
polymeras
chain
reaction
rtpcr
cutoff
valu
select
accuraci
level
twograph
receiv
oper
characterist
analysi
specif
sa
ebov
neg
serum
panel
n
rang
gp
elisa
wag
elisa
diagnost
specif
sl
ebov
neg
panel
n
three
elisa
diagnost
sensit
rtpcr
confirm
ebod
patient
depend
time
serum
collect
onset
diseas
significantli
increas
week
postonset
reach
sensit
wag
np
gp
ielisa
develop
diagnost
assay
address
limit
laboratori
infrastructur
resourc
personnel
affect
area
fulfil
requir
pointofcar
poc
rapid
diagnost
test
rdt
includ
realtim
reversetranscript
polymeras
chain
reaction
rtpcr
base
cepheid
genexpert
technolog
antigen
detect
later
flow
immunoassay
ebola
viru
ebov
poc
rdt
molecular
virolog
method
success
develop
evalu
serolog
diagnosi
diseas
serosurveil
control
program
monitor
immun
respons
vaccin
remain
challeng
subject
due
unavail
valid
serolog
assay
collect
diagnost
specimen
viral
clearanc
inappropri
transport
method
storag
condit
may
neg
impact
molecular
assay
make
serolog
test
import
tool
public
health
respons
outbreak
occur
remot
locat
limit
resourc
avail
serolog
test
enzymelink
immunosorb
assay
elisa
use
detect
antibodi
respons
antigen
associ
filoviru
infect
vaccin
establish
assay
depend
product
high
qualiti
immunoreag
recombin
antigen
technolog
offer
advantag
develop
product
biosafeti
level
two
condit
recombin
filovir
nucleoprotein
np
ideal
target
elisa
due
high
immunogen
abund
infect
cell
np
filovirus
highli
conserv
elisa
base
recombin
ebov
np
antigen
report
crossreact
sera
human
anim
infect
differ
filoviru
speci
recombin
np
therefor
use
genusspecif
screen
elisa
specif
filoviru
speci
patient
infect
unknown
glycoprotein
gp
anoth
ideal
antigen
filoviru
elisa
contain
epitop
known
target
filovirusneutr
antibodi
respons
contrari
np
gp
highli
divers
use
elisa
main
purpos
detect
speciesspecif
filovir
antibodi
recombin
proteinbas
elisa
filovirus
first
develop
prehaud
colleagu
assay
made
use
either
recombin
np
antigen
express
escherichia
coli
e
coli
system
recombin
gp
antigen
express
baculovirusspodoptera
frugiperda
cell
express
system
antigen
react
posit
sera
previous
ebovinfect
human
patient
sever
group
sinc
use
adapt
protein
express
techniqu
develop
serolog
assay
ebov
report
high
sensit
specif
detect
antiebov
igg
howev
recombin
antigen
express
bacteri
express
system
often
problemat
due
lack
molecular
fold
posttransl
modif
glycosyl
recombin
antigen
express
baculovirusinsect
cell
system
prevail
problem
present
express
bacteri
express
system
antigen
properti
antigen
may
consider
affect
differ
glycosyl
pathway
insect
mammalian
cell
overcom
abovement
problem
nakayama
colleagu
develop
first
filoviru
elisa
base
recombin
histidinetag
gp
express
human
embryon
kidney
cell
use
mammalian
express
vector
pcaggsmc
vu
colleagu
develop
optim
evalu
similar
elisa
quantif
antibodi
ebov
vaccin
nonhuman
primat
human
sampl
unavail
test
fieldvalid
elisa
base
commerci
avail
recombin
ebov
gp
report
detect
immunoglobulin
g
igg
oral
fluid
howev
due
lower
sensit
oral
fluidbas
assay
compar
serumbas
assay
risk
misdiagnos
patient
low
oral
concentr
antiebov
igg
although
number
new
gener
filoviru
serolog
assay
develop
recent
year
none
adequ
valid
date
detect
igg
sera
ebovinfect
human
larg
due
difficulti
obtain
panel
clinic
materi
suffici
size
allow
statist
sound
evalu
nevertheless
valid
serolog
assay
determin
basic
diagnost
perform
paramet
essenti
report
diagnost
result
compar
patient
result
differ
diagnost
laboratori
evalu
elisa
efficaci
highmort
occurr
ebola
diseas
ebod
outbreak
almost
year
last
three
decad
great
public
health
concern
unpreced
first
epidem
ebod
west
africa
largescal
reemerg
ebod
democrat
republ
congo
exemplifi
devast
health
humanitarian
socioeconom
impact
challeng
contain
ebod
outbreak
resourcepoor
polit
conflict
set
increas
incid
sever
size
ebod
outbreak
highlight
import
develop
standard
diagnost
tool
ebod
rapid
diagnosi
postepidem
surveil
devast
ebod
outbreak
date
west
african
outbreak
prompt
determin
seropreval
rate
infect
risk
popul
studi
assess
occurr
asymptomat
infect
purpos
studi
evalu
compar
diagnost
perform
ebov
iggindirect
elisa
base
antigen
produc
classic
virolog
recombin
protein
express
method
use
human
serum
panel
ebov
noninfect
ebov
infect
human
total
individu
bank
sera
collect
south
africa
sa
sierra
leon
sl
use
sa
sera
n
origin
submit
variou
routin
diagnost
test
centr
emerg
zoonot
parasit
diseas
nation
institut
communic
diseas
nicd
johannesburg
sera
repres
specimen
collect
individu
ebov
nonendem
countri
regard
igg
ebov
neg
refer
serum
panel
ethic
clearanc
use
sa
human
bank
sera
develop
valid
diagnost
assay
obtain
human
ethic
committe
univers
witwatersrand
johannesburg
sa
clearanc
certif
februari
sl
blood
specimen
origin
submit
ebov
rtpcr
test
sa
modular
highbiosafeti
field
ebola
diagnost
laboratori
fedl
establish
august
near
freetown
intern
respons
rapidli
increas
number
ebod
case
sl
select
aliquot
process
sera
ship
dri
ice
fedl
nicd
biosafeti
level
bsl
total
sera
obtain
sl
patient
suspect
ebod
august
march
use
sera
ebov
rtpcr
confirm
case
date
diseas
onset
record
ebod
case
submiss
form
ribonucl
acid
blood
extract
use
qiaamp
viral
rna
kit
qiagen
hilden
germani
accord
manufactur
instruct
rtpcr
perform
use
qiagen
onestep
rtpcr
kit
qiagen
hilden
germani
per
manufactur
instruct
use
previous
describ
primer
probe
target
ebov
l
gene
specimen
ct
valu
consid
posit
ebov
rna
thu
confirm
ebov
infecti
statu
patient
serum
specimen
sl
ebov
rtpcr
posit
patient
regard
sl
refer
posit
serum
panel
remain
specimen
ebov
rtpcr
neg
individu
whose
sera
test
neg
antiebov
igg
igg
elisa
evalu
studi
use
cutoff
deriv
sa
igg
ebov
neg
refer
serum
panel
serum
panel
regard
sl
refer
neg
serum
panel
sourc
posit
control
serum
c
import
ebod
case
gabon
sa
case
gabones
physician
brought
librevil
gabon
octob
admit
privat
hospit
johannesburg
nurs
die
infect
exposur
blood
neg
control
serum
refer
cezpd
svpl
obtain
south
african
blood
servic
test
neg
antiebov
igg
igm
antibodi
inhous
elisa
use
procedur
publish
ksiazek
et
al
intern
qualiti
control
iqc
data
gener
describ
previous
upper
lower
control
iqc
limit
togeth
coeffici
variat
replic
posit
intern
control
serum
test
sera
appli
assay
accept
criteria
diagnost
perform
three
indirect
elisa
ielisa
detect
antiebov
igg
antibodi
human
sera
evalu
elisa
base
antigen
prepar
infect
cell
lysat
recombin
antigen
produc
bacteri
mammalian
express
system
ebov
whole
antigen
wag
produc
previous
describ
modif
vero
cell
atcc
manassa
va
usa
infect
spu
isol
ebov
passag
vero
cell
isol
serum
nurs
contract
fatal
infect
gabones
physician
admit
privat
hospit
south
africa
incub
c
cytopath
effect
observ
cell
supernat
collect
snap
freezethaw
c
c
lyse
cell
supernat
separ
centrifug
g
c
min
collect
supernat
gamma
irradi
gy
inactiv
viru
satur
ammonium
sulphat
solut
sigma
aldrich
merck
kenilworth
nj
usa
slowli
ad
constant
stir
irradi
supernat
final
concentr
mixtur
incub
c
overnight
antigencontain
pellet
precipit
collect
centrifug
g
min
c
resuspend
one
tenth
origin
supernat
volum
phospat
buffer
salin
pb
ph
antigen
dialys
pb
remov
ammonium
suphat
buffer
chang
wag
prepar
aliquot
store
c
use
uninfect
vero
cell
prepar
way
use
control
antigen
codon
optim
nucleotid
sequenc
ebov
nucleocapsid
np
genbank
access
number
synthes
ctermin
glycin
linker
histidin
tag
genscript
piscataway
nj
usa
subclon
ncoi
xhoi
restrict
site
express
vector
novagen
merck
usa
sequenc
verifi
plasmid
zebov
np
use
transform
compet
star
e
coli
starter
cultur
grown
overnight
c
dilut
fold
allow
reach
exponentialphas
growth
od
protein
express
induc
use
mm
iptg
sigma
aldrich
merck
usa
h
c
vigor
shake
cell
harvest
centrifug
resuspend
sodium
phosphat
buffer
mm
nah
hpo
mm
nacl
ph
lyse
use
combin
bugbust
lysonas
novagen
merck
usa
treatment
freezethaw
cycl
sonic
recombin
np
proteincontain
solubl
phase
collect
high
speed
centrifug
g
min
c
load
onto
profin
imac
biorad
hercul
ca
usa
cobaltcharg
resin
protein
left
bind
overnight
gentl
shake
c
use
ratio
ml
resin
ml
solubl
protein
fraction
contamin
protein
remov
wash
resin
twice
packedresin
volum
sodium
phosphat
buffer
contain
mm
imidazol
ph
use
gentl
centrifug
g
min
c
recombin
np
elut
overnight
gentl
shake
c
packedresin
volum
sodium
phosphat
buffer
contain
mm
imidazol
ph
elut
protein
dialys
carbonatebicarbon
buffer
ph
sigma
aldrich
merck
usa
remov
residu
contamin
protein
purifi
protein
pass
sec
size
exclus
column
biorad
hercul
ca
usa
fraction
contain
np
collect
collect
fraction
pool
concentr
use
amicon
ultra
filter
millipor
merck
usa
kd
cutoff
purifi
np
quantifi
use
bradford
concentr
assay
kit
pierc
thermofish
scientif
waltham
usa
aliquot
store
c
later
use
control
antigen
process
follow
use
express
vector
without
insert
recombin
ebov
glycoprotein
gp
antigen
express
human
embryon
kidney
cell
obtain
integr
biotherapeut
rockvil
md
usa
optim
immunoreag
concentrationswork
dilut
ielisa
determin
use
standard
checkerboard
titrat
procedur
microtit
plate
maxisorb
immunopl
nunc
roskild
denmark
wag
np
gp
ielisa
respect
coat
wag
correspond
control
antigen
np
correspond
control
antigen
gp
wag
np
ielisa
viru
control
antigen
ad
row
top
half
plate
row
ad
bottom
half
plate
row
eh
respect
gp
ielisa
row
row
ah
coat
commerci
gp
control
antigen
avail
np
correspond
control
antigen
dilut
stock
concentr
mgml
carbonatebicarbon
buffer
ph
antigen
dilut
phosphat
pb
without
mg
ca
ph
wag
uninfect
vero
cell
cultur
antigen
dilut
gp
dilut
stock
concentr
mgml
plate
four
replic
posit
serum
control
c
two
replic
neg
serum
control
two
replic
conjug
control
cc
wag
np
ielisa
c
ad
well
b
coat
viru
antigen
correspond
well
e
f
coat
control
antigen
accordingli
ad
c
g
cc
diluent
buffer
ad
h
remain
well
ad
eh
use
test
test
sera
duplic
test
serum
ad
well
correspond
ad
remain
test
sera
follow
layout
principl
gp
ielisa
control
antigen
intern
control
place
follow
c
well
b
well
c
cc
well
remain
well
ad
eh
use
test
test
sera
duplic
test
serum
ad
well
accordingli
test
serum
ad
well
reagent
ad
immunopl
volum
unless
otherwis
state
passiv
adsorpt
onto
elisa
plate
perform
c
overnight
subsequ
incub
except
substrat
addit
perform
c
humidifi
chamber
h
follow
coat
plate
wash
time
pb
contain
tween
wash
procedur
follow
subsequ
stage
ielisa
plate
block
nonfat
milk
powder
pb
incub
plate
wash
control
test
sera
dilut
nonfat
milk
powder
pb
diluent
buffer
ad
test
serum
neg
control
serum
conjug
control
test
duplic
posit
control
test
quadrupl
follow
incub
sera
plate
wash
goat
antihuman
igg
hrpo
conjug
invitrogen
thermofish
scientif
usa
dilut
diluent
buffer
ad
well
incub
plate
wash
sulfon
acid
abt
peroxidas
seracar
lifesci
milford
usa
substrat
ad
well
plate
incub
dark
room
temperatur
c
min
reaction
stop
addit
sodium
dodecyl
sulphat
sd
optic
densiti
od
read
measur
nm
od
read
convert
percentag
posit
intern
control
serum
pp
use
equat
previous
describ
briefli
specif
activ
serum
net
od
calcul
subtract
nonspecif
background
od
well
control
antigen
od
well
viru
antigen
np
wag
ielisa
mean
net
od
read
convert
pp
use
formula
pp
mean
net
test
serummean
net
od
posit
control
cutoff
valu
determin
mean
standard
deviat
sd
pp
valu
record
sa
sl
igg
ebov
neg
serum
panel
also
select
accuraci
level
misclassif
cost
term
mct
option
twograph
receiv
oper
characterist
tgroc
analysi
avail
microsoft
excel
redmond
wa
usa
use
sl
refer
igg
ebov
neg
posit
serum
panel
coeffici
variat
cv
valu
calcul
measur
rel
variabl
use
formula
cv
sd
replicatesmean
replic
optimis
cutoff
valu
mct
tgroc
base
follow
equat
compar
diagnost
perform
assay
agreement
result
match
test
sampl
data
analyz
stata
use
mcnemar
test
cohen
kappa
statist
evalu
effect
serum
inactiv
level
detect
antiebov
igg
wag
np
gp
ielisa
laboratori
protocol
previous
shown
complet
inactiv
ebov
viru
human
serum
use
briefli
c
first
dilut
pb
contain
either
triton
sigmaaldrich
taufkichen
germani
heat
c
min
twofold
log
dilut
log
untreat
treat
serum
test
ielisa
dilut
test
duplic
separ
run
serum
titer
consid
highest
sampl
dilut
pp
valu
ielisa
cutoff
least
six
replic
within
run
c
od
read
wag
np
gp
ielisa
within
iqc
lower
lcl
upper
ucl
control
limit
within
run
averag
cv
rang
np
ielisa
gp
ielisa
run
averag
cv
rang
np
ielisa
gp
ielisa
tabl
within
run
cc
od
read
within
iqc
lcl
ucl
wag
np
gp
ielisa
iqc
od
control
limit
rang
iqc
od
control
limit
rang
respect
distribut
ielisa
pp
valu
determin
cutoff
mean
plu
three
standard
deviat
pp
valu
record
test
sa
sl
ebov
igg
neg
serum
panel
shown
figur
select
optim
cutoff
mct
tgroc
sl
serum
panel
shown
figur
mct
trroc
base
nonparametr
program
option
due
departur
normal
distribut
data
set
analyz
pp
threshold
valu
assay
similar
irrespect
serum
panel
analyz
method
use
determin
cutoff
figur
figur
wag
ielisa
figur
figur
np
ielisa
figur
figur
gp
ielisa
respect
higher
cutoff
valu
gp
ielisa
like
due
higher
elisa
nois
result
includ
control
antigen
assay
irrespect
data
set
analyz
cutoff
use
three
assay
evalu
studi
high
estim
dsp
rang
sa
sl
neg
serum
panel
howev
dsp
gp
ielisa
gener
lower
sa
neg
serum
panel
tabl
mct
trroc
base
nonparametr
program
option
due
departur
normal
distribut
data
set
analyz
pp
threshold
valu
assay
similar
irrespect
serum
panel
analyz
method
use
determin
cutoff
figur
figur
figur
gp
ielisa
respect
higher
cutoff
valu
gp
ielisa
like
due
higher
elisa
nois
result
includ
control
antigen
assay
irrespect
data
set
analyz
cutoff
use
three
assay
evalu
studi
high
estim
dsp
rang
sa
sl
neg
serum
panel
howev
dsp
gp
ielisa
gener
lower
sa
neg
serum
panel
tabl
individu
result
yield
wag
np
gp
ielisa
sera
rtpcr
confirm
ebod
case
differ
time
post
diseas
onset
use
differ
cutoff
valu
given
tabl
irrespect
cutoff
use
result
similar
assay
np
ielisa
sensit
detect
igg
antibodi
first
two
week
post
diseas
onset
compar
wag
gp
ielisa
latter
least
sensit
exampl
use
tgroc
deriv
threshold
ebod
patient
bled
two
week
post
onset
posit
wag
np
gp
ielisa
respect
mc
nemar
test
indic
disagr
diagnost
capac
combin
dse
dsp
np
wag
p
gp
ielisa
p
respect
use
sierra
leon
data
n
agreement
found
wag
gp
ielisa
p
discrep
nonmatch
result
record
first
two
week
post
diseas
onset
two
week
post
onset
detect
igg
antibodi
agreement
assay
significantli
improv
sera
test
day
post
onset
test
posit
wag
np
ieliss
irrespect
cutoff
use
depend
cutoff
posit
gp
ielisa
tabl
mc
nemar
test
indic
agreement
np
wag
gp
ielisa
rang
use
data
nonebod
diseas
patient
bled
day
later
postonset
n
except
gp
wag
np
ielisa
cutoff
respect
p
estim
dse
sera
collect
differ
time
post
diseas
onset
given
tabl
mean
level
igg
respons
measur
wag
np
gp
ielisa
ebod
rtpcr
confirm
case
bled
differ
time
diseas
onset
shown
figur
averag
first
seroconvers
detect
np
day
day
np
wag
day
post
onset
ielisa
mean
level
igg
measur
ielisa
significantli
differ
estim
dse
sera
collect
differ
time
post
diseas
onset
given
tabl
day
post
onset
dse
rang
gp
ielisa
np
ielisa
day
post
onset
dse
wag
np
ielisa
irrespect
cutoff
use
rang
gp
ielisa
tabl
diagnost
sensit
whole
antigen
wag
nucleocapsid
np
glycoprotein
gp
ielisa
detect
antiigg
ebov
antibodi
human
cutoff
pp
wag
ielisa
wag
ielisa
wag
ielisa
mean
level
igg
respons
measur
wag
np
gp
ielisa
ebod
rtpcr
confirm
case
bled
differ
time
diseas
onset
shown
figur
averag
first
seroconvers
detect
np
day
day
np
wag
day
post
onset
ielisa
mean
level
igg
measur
ielisa
significantli
differ
differ
inactiv
protocol
use
advers
effect
kinet
detect
level
antiebov
igg
c
either
ielisa
evalu
studi
titer
tabl
well
kinet
doserespons
curv
figur
similar
inactiv
assay
diagnost
decis
limit
cutoff
repres
serolog
assay
test
valu
use
dichotom
neg
posit
result
infer
defin
infect
statu
individu
specif
pathogen
diseas
relev
data
use
determin
cutoff
consequ
impact
estim
dse
dsp
measur
test
perform
import
consider
determin
serolog
assay
cutoff
select
sera
unequivoc
infect
individu
sera
individu
never
infect
agent
question
also
order
account
distribut
covari
factor
genet
nutrit
geograph
stage
infect
may
influenc
estim
dse
dsp
target
popul
prefer
sampl
use
simpl
random
systemat
stratifi
sampl
method
ideal
condit
could
appli
studi
assay
valid
data
prefer
deriv
test
sampl
refer
individu
known
histori
infect
statu
also
countri
region
test
use
tradit
gold
standard
select
truli
infect
uninfect
subject
includ
isol
agent
pathognomon
histopatholog
criteria
true
gold
standard
difficult
accomplish
rel
standard
comparison
often
necessari
includ
result
serolog
assay
order
ensur
ebov
true
infect
statu
individu
whose
sera
use
studi
rtpcr
neg
sera
test
neg
antiebov
igg
igg
elisa
use
cutoff
deriv
sa
igg
ebov
neg
refer
serum
panel
regard
sl
refer
neg
serum
panel
serum
specimen
sl
ebov
rtpcr
posit
patient
known
date
diseas
onset
regard
sl
refer
posit
serum
panel
variou
statist
analys
use
studi
select
cutoff
valu
provid
similar
result
cutoff
valu
determin
two
three
sd
mean
uninfect
individu
frequent
use
interpret
serodiagnost
test
howev
assum
normal
distribut
test
valu
popul
target
assay
provid
estim
dsp
deviat
normal
often
record
serolog
data
address
select
threshold
valu
therefor
also
use
tgroc
analysi
select
optim
cutoff
valu
account
parametr
versu
nonparametr
distribut
test
valu
ielisa
evalu
studi
high
estim
dsp
dse
depend
time
serum
taken
post
diseas
onset
high
detect
rate
diagnost
decis
limit
cutoff
repres
serolog
assay
test
valu
use
dichotom
neg
posit
result
infer
defin
infect
statu
individu
specif
pathogen
diseas
relev
data
use
determin
cutoff
consequ
impact
estim
dse
dsp
measur
test
perform
import
consider
determin
serolog
assay
cutoff
select
sera
unequivoc
infect
individu
sera
individu
never
infect
agent
question
also
order
account
distribut
covari
factor
genet
nutrit
geograph
stage
infect
may
influenc
estim
dse
dsp
target
popul
prefer
sampl
use
simpl
random
systemat
stratifi
sampl
method
ideal
condit
could
appli
studi
assay
valid
data
prefer
deriv
test
sampl
refer
individu
known
histori
infect
statu
also
countri
region
test
use
tradit
gold
standard
select
truli
infect
uninfect
subject
includ
isol
agent
pathognomon
histopatholog
criteria
true
gold
standard
difficult
accomplish
rel
standard
comparison
often
necessari
includ
result
serolog
assay
order
ensur
ebov
true
infect
statu
individu
whose
sera
use
studi
rtpcr
neg
sera
test
neg
antiebov
igg
igg
elisa
use
cutoff
deriv
sa
igg
ebov
neg
refer
serum
panel
regard
sl
refer
neg
serum
panel
serum
specimen
sl
ebov
rtpcr
posit
patient
known
date
diseas
onset
regard
sl
refer
posit
serum
panel
variou
statist
analys
use
studi
select
cutoff
valu
provid
similar
result
cutoff
valu
determin
two
three
sd
mean
uninfect
individu
frequent
use
interpret
serodiagnost
test
howev
assum
normal
distribut
test
valu
popul
target
assay
provid
estim
dsp
deviat
normal
often
record
serolog
data
address
select
threshold
valu
therefor
also
use
tgroc
analysi
select
optim
cutoff
valu
account
parametr
versu
nonparametr
distribut
test
valu
ielisa
evalu
studi
high
estim
dsp
dse
depend
time
serum
taken
post
diseas
onset
high
detect
rate
antiebov
igg
rtpcr
ebov
confirm
case
record
two
week
post
diseas
onset
result
previou
studi
small
number
ebod
patient
kikwit
democrat
republ
congo
suggest
mani
patient
antibodi
earli
cours
ill
mani
may
die
without
develop
detect
antibodi
ebov
therefor
measur
igg
antibodi
rather
limit
use
diagnosi
acut
ebod
case
ielisa
repres
one
simplest
elisa
format
difficult
valid
signal
amplif
specif
nonspecif
compon
reason
determin
specif
bind
antibodi
sera
test
specif
viral
antigen
correspond
control
comparison
antigen
account
possibl
nonspecif
background
activ
gp
ielisa
evalu
studi
base
commerci
avail
recombin
gp
neg
control
could
obtain
compar
wag
np
ielisa
includ
control
antigen
higher
gp
ielisa
test
valu
ebov
neg
serum
panel
consequ
higher
pp
cutoff
valu
deriv
assay
like
due
control
antigen
due
inher
differ
amongst
assay
system
bindingantibodi
level
express
rel
rather
absolut
term
one
advantag
use
pp
valu
measur
antibodi
activ
ielisa
method
od
read
convers
assum
uniform
background
activ
therefor
also
suitabl
interlaboratori
standard
first
elisa
detect
antibodi
ebov
base
whole
antigen
prepar
infect
cell
lysat
variat
assay
still
wide
use
diagnost
research
laboratori
whole
filoviru
antigen
rel
easili
produc
larg
volum
prepar
pose
health
risk
restrict
product
biosafeti
level
facil
facil
expens
construct
oper
also
easili
avail
access
countri
fatal
filovirus
endem
addit
bind
antibodi
cellular
contamin
present
ebovinfect
cell
lysat
may
lead
crossreact
result
reduc
specif
high
qualiti
filoviru
recombin
protein
antigen
safe
prepar
without
need
high
biocontain
facil
outsid
ebov
endem
area
use
elisa
potenti
reduc
risk
fals
posit
result
allow
better
standard
test
clinic
specimen
potenti
contain
viral
agent
present
seriou
biohazard
number
inactiv
method
shown
complet
inactiv
ebov
also
markedli
alter
protein
compon
human
blood
eg
enzym
coagul
factor
result
viral
inactiv
protocol
evalu
studi
indic
alter
detect
level
anti
ebovigg
thu
togeth
recombin
antigen
base
elisa
provid
safe
reliabl
test
platform
previous
report
use
singl
filovir
protein
antigen
disadvantag
filoviru
serolog
sera
patient
infect
ebov
contain
antibodi
sever
viral
protein
therefor
might
display
reduc
activ
later
seroconvers
elisa
base
singl
recombin
antigen
result
studi
indic
antiebov
np
igg
detect
earlier
antiebov
gp
igg
antibodi
first
week
post
diseas
onset
like
due
higher
abund
highli
immunogen
protein
infect
cell
longlast
persist
igg
antibodi
human
infect
ebov
render
igg
detect
elisa
suitabl
tool
epidemiolog
investig
evalu
efficaci
filoviru
vaccin
therapeut
requir
monitor
immun
respons
correl
protect
surviv
use
reliabl
reproduc
serolog
method
antiebov
gp
igg
elisa
recent
shown
reproduc
quantifi
level
antiebov
igg
antibodi
sera
ebod
survivor
immun
individu
thu
offer
import
laboratori
tool
assess
immunogen
candid
ebov
vaccin
np
igg
ielisa
evalu
studi
potenti
use
test
immun
evalu
protect
natur
ebov
exposur
individu
immun
ebov
gpbase
vaccin
receiv
antiebov
gp
passiv
immun
highli
accur
robust
safe
test
elisa
base
recombin
ebov
antigen
potenti
replac
tradit
serolog
diagnost
method
pose
health
risk
thu
necessit
use
high
biocontain
facil
practic
simpl
viral
inactiv
protocol
evalu
studi
alter
measur
level
anti
ebovigg
thu
togeth
recombin
antigen
base
elisa
provid
safe
test
applic
longlast
igg
antibodi
make
detect
use
epidemiolog
investig
